Elevance Health Inc. (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.

Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.

Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.

Elevance Health shares rose 1.8% to $397.20 in pre-market trading.

These analysts made changes to their price targets on Elevance Health following earnings announcement.

• Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.
• Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.
• Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.

Considering buying ELV stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.